-Economic and Political Weekly The National Democratic Alliance government has constituted the IPR Think Tank which, among other things, is to draft the National Intellectual Property Rights Policy. India may not have a policy per se but it has a strong legislation on IPRs, a functioning patents office and mechanisms to grant patents as well as protect consumer interests. The Think Tank has other issues it needs to address, but is...

-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Times of India NEW DELHI: All life saving Drugs from January 2015 will come with a bold red strip on their packs highlighting price as fixed by the government and also specify if they are under price control. Signaling a New Year gift for consumers, the government is set to make it mandatory for regulated Drugs to print on their packs 'DPCO Scheduled Drug' in black ink on a bold...

-The Times of India NEW DELHI: Top selling medicine brands for stress, hypertension, HIV, pain and pneumonia may soon become cheaper. The drug price regulator National Pharmaceutical Pricing Authority (NPPA) is set to bring in at least 100 new Drugs under price control to include combinations, dosages and strengths that are commonly prescribed by doctors and sold by pharmacists. For instance, currently only one strength of Paracetamol is under price control, whereas...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...